NEFL and myeloid sarcoma: Historically, one has to name multiple sclerosis (MS) first, where concentrations of serum neurofilament light chains (sNfL) have shaped into a piece in the puzzle that is monitoring of disease and prediction of outcome or therapeutic response8–10.